FENC
Fennec Pharmaceuticals IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$227.02M
P/E Ratio
—
EPS
$-0.34
Beta
0.93
52W High
$9.92
52W Low
$5.65
50-Day MA
$7.11
200-Day MA
$7.98
Dividend Yield
—
Profit Margin
-21.80%
Forward P/E
20.96
PEG Ratio
1.47
About Fennec Pharmaceuticals Inc
Fennec Pharmaceuticals Inc., a biopharmaceutical company, develops candidate products for use in the treatment of cancer in the United States. The company is headquartered in Research Triangle Park, North Carolina.
Fundamentals
| Revenue (TTM) | $44.64M |
| Gross Profit (TTM) | $40.88M |
| EBITDA | $-6.18M |
| Operating Margin | -18.50% |
| Return on Equity | -65.80% |
| Return on Assets | -6.80% |
| Revenue/Share (TTM) | $1.56 |
| Book Value | $1.04 |
| Price-to-Book | 6.39 |
| Price-to-Sales (TTM) | 5.09 |
| EV/Revenue | 4.223 |
| EV/EBITDA | 20.27 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 73.80% |
| Shares Outstanding | $34.71M |
| Float | $16.86M |
| % Insiders | 14.29% |
| % Institutions | 53.66% |
Historical Volatility
HV 10-Day
62.61%
HV 20-Day
63.37%
HV 30-Day
91.84%
HV 60-Day
70.85%
HV Rank
100.0%
Volatility is currently contracting
Analyst Ratings
Consensus ($15.17 target)
1
Strong Buy5
BuyMore HEALTHCARE Stocks
Data last updated: 5/2/2026